THERAXEN Trademark

Trademark Overview

On Thursday, September 22, 2016, a trademark application was filed for THERAXEN with the United States Patent and Trademark Office. The USPTO has given the THERAXEN trademark a serial number of 87179890. The federal status of this trademark filing is REGISTERED as of Tuesday, July 9, 2019. The THERAXEN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Biomedical services, namely, research, development, and product design for pharmaceutical products involved in the diagnosis and treatment of human diseases; Biomedical services, namely, pharmaceutical research and development, modeling and testing of pharmaceuticals and cancer diagnostic and treatment therapies; Biomedical and Laboratory services, namely, biologic assay development, preclinical pharmaceutical research, clinical research, clinical trial management, and providing in silico screening and in vitro testing of small molecules targeting Guanine nucleotide exchange factors ("GEF"s), all for pharmaceutical product research, discovery, and development purposes; consulting and advising on scientific research in the fields of small molecules and drug discovery
theraxen

General Information

Serial Number87179890
Word MarkTHERAXEN
Filing DateThursday, September 22, 2016
Status700 - REGISTERED
Status DateTuesday, July 9, 2019
Registration Number5800746
Registration DateTuesday, July 9, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 13, 2018

Trademark Statements

Goods and ServicesBiomedical services, namely, research, development, and product design for pharmaceutical products involved in the diagnosis and treatment of human diseases; Biomedical services, namely, pharmaceutical research and development, modeling and testing of pharmaceuticals and cancer diagnostic and treatment therapies; Biomedical and Laboratory services, namely, biologic assay development, preclinical pharmaceutical research, clinical research, clinical trial management, and providing in silico screening and in vitro testing of small molecules targeting Guanine nucleotide exchange factors ("GEF"s), all for pharmaceutical product research, discovery, and development purposes; consulting and advising on scientific research in the fields of small molecules and drug discovery

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 27, 2016
Primary Code042
First Use Anywhere DateSaturday, September 30, 2017
First Use In Commerce DateSaturday, September 30, 2017

Trademark Owner History

Party NameNOT AVAILABLE
Party Type30 - Original Registrant
Legal Entity Type01 - Individual
AddressOro Valley, AZ 85704
Party NameNOT AVAILABLE
Party Type20 - Owner at Publication
Legal Entity Type01 - Individual
AddressOro Valley, AZ 85704
Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressOro Valley, AZ 85704

Trademark Events

Event DateEvent Description
Sunday, January 1, 2017NON-FINAL ACTION E-MAILED
Monday, September 26, 2016NEW APPLICATION ENTERED
Tuesday, September 27, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 29, 2016ASSIGNED TO EXAMINER
Sunday, January 1, 2017NON-FINAL ACTION WRITTEN
Sunday, January 1, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 22, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 22, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 23, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 13, 2017FINAL REFUSAL WRITTEN
Thursday, July 13, 2017FINAL REFUSAL E-MAILED
Tuesday, January 2, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 13, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, January 2, 2018TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, January 2, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 13, 2018PUBLISHED FOR OPPOSITION
Wednesday, January 3, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 24, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, September 24, 2018USE AMENDMENT FILED
Thursday, October 18, 2018STATEMENT OF USE PROCESSING COMPLETE
Thursday, June 6, 2019SU-EXAMINER'S AMENDMENT WRITTEN
Thursday, June 6, 2019EXAMINERS AMENDMENT E-MAILED
Thursday, June 6, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, June 6, 2019ASSIGNED TO LIE
Tuesday, February 13, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 10, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, September 24, 2018TEAS STATEMENT OF USE RECEIVED
Thursday, October 18, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, November 8, 2018SU - NON-FINAL ACTION - WRITTEN
Thursday, November 8, 2018NON-FINAL ACTION E-MAILED
Thursday, November 8, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 6, 2019EXAMINER'S AMENDMENT ENTERED
Thursday, June 6, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, June 7, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, July 9, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, July 9, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

theraxen research development pharmaceutical namely biomedical services small treatment clinical testing